Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Nikita Acharekar"'
Autor:
Zeng-Hui Wei, Jagadish Koya, Nikita Acharekar, Jesus Trejos, Xing-Duo Dong, Francis A. Schanne, Charles R. Ashby, Sandra E. Reznik
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-16 (2023)
Abstract Alzheimer’s disease (AD) is a chronic degenerative brain disorder with no clear pathogenesis or effective cure, accounting for 60–80% of cases of dementia. In recent years, the importance of neuroinflammation in the pathogenesis of AD an
Externí odkaz:
https://doaj.org/article/893fcb60e9304622ad9b4df38e80801f
Autor:
Zhuo-Xun Wu, Qiu-Xu Teng, Yuqi Yang, Nikita Acharekar, Jing-Quan Wang, Min He, Sabesan Yoganathan, Jun Lin, Jian Wang, Zhe-Sheng Chen
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 12, Iss 5, Pp 2609-2618 (2022)
Overexpression of ABCG2 transporter in cancer cells has been linked to the development of multidrug resistance (MDR), an obstacle to cancer therapy. Our recent study uncovered that the MET inhibitor, tepotinib, is a potent reversal agent for ABCB1-me
Externí odkaz:
https://doaj.org/article/290b0cda90f24d6583e11b6b86866a8c
Autor:
Silpa Narayanan, Qiu-Xu Teng, Zhuo-Xun Wu, Urooj Nazim, Nishant Karadkhelkar, Nikita Acharekar, Sabesan Yoganathan, Najia Mansoor, Feng-Feng Ping, Zhe-Sheng Chen
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Colorectal cancer is a major health problem, and it is the third most diagnosed cancer in the United States. The current treatment for colorectal cancer includes irinotecan, a topoisomerase I inhibitor, and other targeted drugs, such as bevacizumab a
Externí odkaz:
https://doaj.org/article/c4b0064563714356822fa7ac6bc96395
Publikováno v:
Cells, Vol 10, Iss 2, p 458 (2021)
Multidrug resistance (MDR) is one of the major clinical challenges in cancer treatment and compromises the effectiveness of conventional anticancer chemotherapeutics. Among known mechanisms of drug resistance, drug efflux via ATP binding cassette (AB
Externí odkaz:
https://doaj.org/article/d9c956eb9f374549967d615ccc68e51c
Autor:
Zhe-Sheng Chen, Silpa Narayanan, Hansu Ma, Zhuo-Xun Wu, Sabesan Yoganathan, Shuo Fang, Yihang Pan, Jing-Quan Wang, Jagadish Koya, Nikita Acharekar
Publikováno v:
International Journal of Biological Sciences
Tyrosine kinase inhibitors (TKIs) are important in managing lymphoid malignancies by targeting B-cell receptor signaling pathways. Entospletinib (GS-9973) is an oral, selective inhibitor of spleen tyrosine kinase (Syk), currently in the phase II clin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01bce6c01d3e313fa64ed0fb82147c94
https://doi.org/10.7150/ijbs.61229
https://doi.org/10.7150/ijbs.61229
Autor:
Zhuo-Xun, Wu, Qiu-Xu, Teng, Yuqi, Yang, Nikita, Acharekar, Jing-Quan, Wang, Min, He, Sabesan, Yoganathan, Jun, Lin, Jian, Wang, Zhe-Sheng, Chen
Publikováno v:
Acta pharmaceutica Sinica. B. 12(5)
Overexpression of ABCG2 transporter in cancer cells has been linked to the development of multidrug resistance (MDR), an obstacle to cancer therapy. Our recent study uncovered that the MET inhibitor, tepotinib, is a potent reversal agent for ABCB1-me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::21c0c43a67017329270d1b2a740ed8ed
https://pubmed.ncbi.nlm.nih.gov/35646541
https://pubmed.ncbi.nlm.nih.gov/35646541
Autor:
Zhuoxun Wu, Qiu-Xu Teng, Yuqi Yang, Nikita Acharekar, Jing-Quan Wang, Min He, Sabesan Yoganathan, Jun Lin, Jian Wang, Zhe-Sheng Chen
Publikováno v:
Cancer Research. 82:409-409
ABCG2/BCRP transporter-mediated Multidrug resistance (MDR) in cancers has been considered as one of the obstacles to the cancer chemotherapy. Our recent study characterized the MET inhibitor tepotinib as a potent ABCB1 inhibitor. In the present study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f5e8dd3c276fab23f4985fedc87f80d
https://doi.org/10.1158/1538-7445.am2022-409
https://doi.org/10.1158/1538-7445.am2022-409